In a report released on May 31, Thomas Smith from SVB Securities reiterated a Buy rating on Eledon Pharmaceuticals (ELDN – Research Report). The company’s shares closed yesterday at $1.93.
According to TipRanks, Smith is a top 100 analyst with an average return of 38.1% and a 48.67% success rate. Smith covers the Healthcare sector, focusing on stocks such as MoonLake Immunotherapeutics, Intercept Pharma, and Keros Therapeutics.
Eledon Pharmaceuticals has an analyst consensus of Strong Buy, with a price target consensus of $18.50, which is an 858.55% upside from current levels. In a report released on May 31, LifeSci Capital also maintained a Buy rating on the stock with a $12.00 price target.
See today’s best-performing stocks on TipRanks >>
Based on Eledon Pharmaceuticals’ latest earnings release for the quarter ending March 31, the company reported a quarterly GAAP net loss of $10.77 million. In comparison, last year the company had a GAAP net loss of $9.86 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Eledon Pharmaceuticals, Inc. (Nasdaq:ELDN) is an immunology-focused biotechnology company utilizing its experience in the CD40/CD40L costimulatory pathway to develop and commercialize precision therapies for persons undergoing organ and cellular transplantation, and for people living with autoimmune and neurodegenerative disease. The company’s lead compound in development is tegoprubart (AT-1501), an anti-CD40L antibody. The company, which was established in 2004, is headquartered in Irvine, CA.
Read More on ELDN:
